Runimotamab (BTRC-4017A) is a HER2 and CD3 T cell-engaging bispecific antibody. Runimotamab can decrease the size of liver tumor spheroids. Runimotamab can be studied in oncology research such as HER2-expressing cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control [1] [2].
In Vitro, Runimotamab, when administered in combination with trastuzumab (HY‑P9907), demonstrates superior antitumor activity against locally advanced or metastatic breast cancer[1].
References:
[1]. Shanu Modi, et al., Abstract CT204: Phase 1a/b study of runimotamab, a HER2 x CD3 T cell-engaging bispecific antibody, administered as a single agent and in combination with trastuzumab in patients with HER2-expressing breast cancer (BC). Cancer Res 15 April 2025; 85 (8_Supplement_2)
[2]. Michal Rudnik, et al., Abstract 2747: Combined investigation of anti-tumor efficacy and liver safety of bispecific T cell engagers in immune-competent high-throughput co-culturing platform. Cancer Res 1 April 2023; 83 (7_Supplement): 2747.
In Vitro, Runimotamab, when administered in combination with trastuzumab (HY‑P9907), demonstrates superior antitumor activity against locally advanced or metastatic breast cancer[1].
References:
[1]. Shanu Modi, et al., Abstract CT204: Phase 1a/b study of runimotamab, a HER2 x CD3 T cell-engaging bispecific antibody, administered as a single agent and in combination with trastuzumab in patients with HER2-expressing breast cancer (BC). Cancer Res 15 April 2025; 85 (8_Supplement_2)
[2]. Michal Rudnik, et al., Abstract 2747: Combined investigation of anti-tumor efficacy and liver safety of bispecific T cell engagers in immune-competent high-throughput co-culturing platform. Cancer Res 1 April 2023; 83 (7_Supplement): 2747.